Log in
NYSE:NVO

Novo Nordisk A/S Stock Forecast, Price & News

$63.89
-2.44 (-3.68 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$63.22
Now: $63.89
$65.49
50-Day Range
$65.82
MA: $69.53
$73.62
52-Week Range
$49.24
Now: $63.89
$73.81
Volume1.94 million shs
Average Volume1.50 million shs
Market Capitalization$150.45 billion
P/E Ratio24.48
Dividend Yield1.12%
Beta0.37
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Read More
Novo Nordisk A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.2Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888
Employees43,526

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.30 billion
Cash Flow$2.55 per share
Book Value$3.65 per share

Profitability

Net Income$5.84 billion

Miscellaneous

Outstanding Shares2,354,800,000
Market Cap$150.45 billion
Next Earnings Date11/6/2020 (Estimated)
OptionableOptionable
$63.89
-2.44 (-3.68 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

How has Novo Nordisk A/S's stock price been impacted by Coronavirus (COVID-19)?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVO stock has increased by 10.4% and is now trading at $63.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Novo Nordisk A/S?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novo Nordisk A/S
.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for Novo Nordisk A/S
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings results on Thursday, August, 6th. The company reported $0.67 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.64 by $0.03. The company had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.49 billion. Novo Nordisk A/S had a net margin of 32.73% and a return on equity of 73.42%.
View Novo Nordisk A/S's earnings history
.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a semi-annual dividend on Friday, August 7th. Shareholders of record on Monday, August 17th will be paid a dividend of $0.7826 per share on Tuesday, August 25th. This represents a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, August 14th.
View Novo Nordisk A/S's dividend history
.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S updated its FY 2020 IntraDay earnings guidance on Friday, October, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20.115-20.69 billion, compared to the consensus revenue estimate of $20.39 billion.

What price target have analysts set for NVO?

10 Wall Street analysts have issued 12 month target prices for Novo Nordisk A/S's shares. Their forecasts range from $72.00 to $72.00. On average, they expect Novo Nordisk A/S's share price to reach $72.00 in the next twelve months. This suggests a possible upside of 12.7% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S
.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 4,680,000 shares, an increase of 19.1% from the August 31st total of 3,930,000 shares. Based on an average daily trading volume, of 962,300 shares, the days-to-cover ratio is presently 4.9 days. Currently, 0.3% of the shares of the stock are sold short.
View Novo Nordisk A/S's Short Interest
.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:
  • Mr. Lars Fruergaard Jørgensen, Pres, CEO & Member of Management Board (Age 54)
  • Mr. Karsten Munk Knudsen, Exec. VP, CFO & Member of the Management Board (Age 49)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP, Chief Scientific Officer & Member of the Management Board (Age 60)
  • Mr. Henrik Ehlers Wulff, Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board (Age 50)
  • Ms. Camilla Sylvest, Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board (Age 48)
  • Ms. Monique Carter, Exec. VP, Head of People & Organisation and Member of Management Board (Age 47)
  • Mr. Maziar Mike Doustdar, Exec. VP, Head of International Operations & Member of the Management Board (Age 50)
  • Mr. Douglas J. Langa, Exec. VP, Head of North America Operations & Member of Management Board (Age 54)
  • Mr. Ludovic Helfgott, Exec. VP, Head of Biopharm & Member of Management Board (Age 46)
  • Mr. Peter Hugreffe Ankersen, Head of Investor Relations & Corp. VP

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.05%), Saratoga Research & Investment Management (0.05%), Calamos Advisors LLC (0.02%), Beacon Investment Advisory Services Inc. (0.01%), QV Investors Inc. (0.01%) and GW Henssler & Associates Ltd. (0.01%).
View institutional ownership trends for Novo Nordisk A/S
.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including GW Henssler & Associates Ltd., Saratoga Research & Investment Management, QV Investors Inc., BBVA USA Bancshares Inc., Envestnet Asset Management Inc., Scout Investments Inc., Clifford Swan Investment Counsel LLC, and Anderson Fisher LLC.
View insider buying and selling activity for Novo Nordisk A/S
.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including CWM LLC, Harbour Investment Management LLC, Bradley Foster & Sargent Inc. CT, Ipswich Investment Management Co. Inc., Calamos Advisors LLC, Reynders McVeigh Capital Management LLC, Pacer Advisors Inc., and FNY Investment Advisers LLC.
View insider buying and selling activity for Novo Nordisk A/S
.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $63.89.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $150.45 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis. Novo Nordisk A/S employs 43,526 workers across the globe.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.